GlassScriptPhysician profile
Kevin J Mott
NPI 1295776201
$33,077.85
in general payments reported to CMS, 2019-2025
44 companies · $2,137 in 2025
The $2,137 reported for 2025 was more than what 89% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $875 · 2021: $1,522 · 2022: $2,034 · 2023: $2,826 · 2024: $2,939 · 2025: $2,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,786 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,786.30 |
| Education | $115.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19,762.62 | 2019-2021 | |
| Abbvie INC. | $2,496.23 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,231.84 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,003.85 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $978.60 | 2019-2025 | Odomzo, Blu-U, Winlevi |
| Genzyme Corporation | $858.58 | 2019-2025 | |
| Janssen Biotech, INC. | $639.08 | 2019-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $637.16 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $622.48 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $597.22 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $579.68 | 2019-2025 | |
| Amgen INC. | $564.16 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $390.87 | 2023-2025 | Sotyktu |
| Helsinn Therapeutics (U.S.), INC. | $311.17 | 2019-2024 | Valchlor |
| Incyte Corporation | $278.40 | 2021-2025 | Opzelura |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $257.17 | 2020-2025 | Cabtreo, Siliq, Jublia |
| Galderma Laboratories, L.P. | $246.07 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.30 | 2022-2024 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $183.53 | 2023-2025 | Zoryve |
| Organogenesis INC. | $175.17 | 2024-2025 | Affinity, Cygnus Dual |
| Almirall LLC | $160.61 | 2019-2025 | Klisyri, Seysara |
| Genentech USA, INC. | $96.51 | 2019-2024 | Erivedge |
| Kyowa Kirin, INC. | $82.50 | 2019-2025 | Poteligeo |
| Vyne Pharmaceuticals INC. | $65.21 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $65.20 | 2021 | |
| Revance Therapeutics, INC. | $65.11 | 2024 | Daxxify |
| Biofrontera INC. | $62.04 | 2019-2025 | |
| Mimedx Group, INC. | $60.69 | 2025 | |
| Convatec INC. | $55.92 | 2024-2025 | |
| Organon LLC | $47.39 | 2023-2024 | Renflexis |
| Dusa Pharmaceuticals, INC. | $42.72 | 2019 | |
| Dermavant Sciences, INC. | $33.10 | 2023-2024 | Vtama |
| Celgene Corporation | $25.48 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.24 | 2022 | |
| Biocon Biologics INC | $24.08 | 2023 | Hulio |
| Dermira, INC. | $20.26 | 2020 | |
| Kerecis Limited | $20.00 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Integra Lifesciences Corporation | $19.67 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Epi Health, LLC | $19.32 | 2022 | |
| Mayne Pharma Commercial LLC | $19.14 | 2019 | |
| Acera Surgical, INC. | $19.02 | 2022 | |
| Dilon Technologies, INC. | $16.85 | 2024 | Hemoblast Bellows |
| Verrica Pharmaceuticals INC. | $13.67 | 2024 | Ycanth |
| Sensus Healthcare, INC. | $9.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Mott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.